Carlyle merges two healthcare AI firms into one RCM platform
What's the deal? Global investment firm CarlyleDealroom has a profile for this one. Try Dealroom → has acquired majority stakes in Knack RCMDealroom has a profile for this one. Try Dealroom → and EqualizeRCM, merging the two US healthcare revenue cycle management (RCM) specialists into a single AI-native platform. The deals were backed by Carlyle Asia Partners VI and Carlyle Asia Partners Growth II funds. Financial terms were not disclosed.
The combined entity creates a delivery network spanning the US, India, and the Philippines, serving physician groups, durable medical equipment (DME) providers, rural hospitals, and specialty care segments.
Knack RCM brings global delivery infrastructure anchored by Workmate, a proprietary platform managing end-to-end revenue cycle workflows. EqualizeRCM adds a payer enrolment platform, a denial prediction tool called Bill Smart, and an AI stack built on large language models and agentic AI.
Both founders — Knack's Rajiv Sharma and EqualizeRCM's Nagi Rao — will reinvest a portion of their proceeds and stay on to preserve client continuity.
Why now? The US healthcare RCM market is growing fast, driven by margin compression, workforce shortages, and the shift to value-based care. "Healthcare providers measure success by their ability to meet payroll, preserve services, and support their communities — not by the amount of automation deployed," said Gautam Barai, chief executive officer of Knack RCM.
Carlyle frames the fragmented specialty RCM landscape as ripe for consolidation, citing prior investments in Indegene, Visionary RCM, and CorroHealth as a template.
What could go wrong? The platform targets the revenue cycle's highest-complexity workflows — rural cost reports, DME intake, and anesthesia billing — rather than high-volume, low-complexity automation. That focus on financially consequential claims categories means integration missteps could be costly if reimbursement errors spike during the merger.
Merging two distinct technology stacks and delivery teams across three countries also carries execution risk, particularly when serving rural hospitals with thin margins and little tolerance for disruption.
The signal: Both Knack RCM and EqualizeRCM are classified as early-growth-stage companies, making Carlyle's simultaneous majority-stake play a bet on assembling scale before either firm matures independently. The approach mirrors Carlyle's earlier healthcare services playbook — backing Indegene, now a late-growth-stage platform — and suggests the firm sees specialty RCM following a similar consolidation-to-scale arc, with AI capabilities as the accelerant.
Read more: news.outsourceaccelerator.com
